Bone Marrow Derived Stem Cells for the Treatment of Rotator Cuff Tears



Status:Recruiting
Conditions:Orthopedic
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:50 - 75
Updated:3/31/2019
Start Date:March 27, 2019
End Date:October 2021
Contact:Anna Ramakrishnan
Email:annarama@stanford.edu
Phone:(650) 497-3597

Use our guide to learn which trials are right for you!

Randomized Control Trial of Bone Marrow Derived Stem Cells Combined With Arthroscopic Surgery Versus Arthroscopic Surgery Only for the Treatment of Rotator Cuff Tears

The primary objective is to determine whether adjunct treatment using bone marrow aspirate
concentrate (BMAC) in conjunction with arthroscopic repair of rotator cuff tears reduces
retear rates compared to a control population undergoing arthroscopic repair without BMAC
administration. The secondary objectives are to (1) evaluate the survival and incorporation
of BMAC labeled cells with MRI imaging using the Ferumoxytol infusion stem cell labeling
technique, and (2) determine if administration of BMAC leads to better clinical outcomes as
measured by ASES, UCLA and Constant scoring metrics.

Rotator cuff repair and regeneration has become a focal point for scientists and surgeons in
search for a biological treatment to improve tendon healing, especially in situations of
unfavorable biological conditions. Recent literature supports harvesting and centrifuging
bone marrow aspirate to produce bone marrow aspirate concentration (BMAC) in hopes that
mesenchymal stem cells in the bone marrow aspirate can promote tendon healing and
regeneration.

This is a single blinded randomized clinical trial using labeled BMAC cells in adults
diagnosed with medium to large, single tears of the rotator cuff. This is a single site study
where at least 45 cases among eligible patients will be identified and randomly assigned to a
either a control (arthroscopic repair without BMAC) group or experimental (arthroscopic
repair with BMAC) group. A power analysis will be performed after enrolling 20 patients to
determine the total number of patients required to reach adequate power.

A patient will receive an infusion of Ferumoxytol 1 day prior to the surgical procedure. An
infusion nurse will be present at all times during the infusion to monitor vitals. On the day
of the surgical procedure patients in the both groups will undergo arthroscopic rotator cuff
repair using a double-row technique. Patients in the experimental group will also undergo
harvesting of bone marrow aspirate from the anterior inferior iliac crest, which will be
centrifuged to about 3-4cc of BMAC and placed beneath the tendon at the bone interface. MRIs
will be completed on days 1 and 7 post-operatively to track retention of the labeled
mesenchymal cells. Ultrasound imaging will be performed at 6 months post-surgery to evaluate
tendon healing. Final MRIs will be obtained at 1 year and 2 years post surgery. Patient
related outcomes will be collected at the pre-operative visit, 3 months, 6 months, 1 year and
2 years post surgery in the forms of ASES, UCLA and Constant scoring.

Inclusion Criteria:

- Adults aged 50-75 patients with MRI confirmed rotator cuff tears sized 1.5-3cm
including supraspinatus with or without an associated partial infraspinatus or
subscapularis tear

- Chronic tear > 3 months

- Failed a minimum of 6 weeks of physical therapy

- Hamada stage 1

- Goutallier staging < 3

Exclusion Criteria:

- Radiographs demonstrating mild to moderate arthritis

- Diagnosis of Inflammatory (RA, JIA etc) or infectious arthritis

- Hamada stage > 2

- Cortisone and/or Hyaluronic acid intra-articular injection within the last 3 months

- Brachial plexus pathology

- Currently pregnant or planning to become pregnant

- Shoulder PRP injection within the last year

- History of iron overload syndrome

- Concurrent surgery for shoulder instability
We found this trial at
1
site
Redwood City, California 94063
Phone: 650-497-3597
?
mi
from
Redwood City, CA
Click here to add this to my saved trials